Bausch + Lomb and Alfa Instruments announced that they have signed an exclusive distribution agreement under which Bausch + Lomb will market and distribute Vitreocare, a line of surgical intraocular dyes from Alfa Instruments.

Bausch + Lomb has formed a strategic partnership with Munich Surgical Imaging GmbH (MSI)—a wholly‐owned subsidiary of Heidelberg Engineering GmbH.

Glaukos announced that it obtained an exclusive global license to develop and market IVMED-80, an experimental pharmacologic therapy for keratoconus from iVeena Delivery Systems.

Haag-Streit has announced the opening of a new state-of-the-art microscope production site in Aesch, Switzerland.

The Eye Institute of West Florida's Robert Weinstock, MD, completed the first commercial cases using the ALLY Adaptive Cataract Treatment System, according to Lensar. 15 laser-assisted cataract surgery procedures were carried out by Dr. Weinstock.

Opthea announced two financing deals to advance OPT-302, a drug candidate for wet age-related macular degeneration (AMD).

Following comments from the European Medicines Agency (EMA) about sepofarsen, ProQR Therapeutics released an update on its ophthalmology activities and will now exclusively concentrate on its Axiomer RNA-editing technology platform.

On August 8, Orbis International launched its first on-site training program on board the Flying Eye Hospital, a fully accredited ophthalmic teaching hospital on board a plane, with assistance from Alcon.

HOYA Vision Care has entered into a strategic joint venture with Chinese eyeglass lens manufacturer Jiangsu Sigo Optical's (JSO) Founder and Chief Executive Officer Liu Jianzhong.

Clearside Biomedical announced it has entered into an agreement with HealthCare Royalty Partners in a deal worth up to $65 million.